InhibrxÂ Inc (INBX)

Name: InhibrxÂ Inc (INBX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: InhibrxÂ Inc (INBX)

Stock Card

$123.41

$-0.52 (-0.42%)

As on 28-Aug-2026 16:00EDT

Market cap

$1,816 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

212.3

Div. Yield

0 %

InhibrxÂ Inc (INBX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 119.38 High: 126.04

52 Week Range

Low: 26.19 High: 155.29

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-17.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0
Debt to Equity

0
Book Value

$-3.6
EPS

$-8.9
Face value

--
Shares outstanding

14,717,660

8 Years Aggregate

CFO

$-528.93 Mln

EBITDA

$-578.39 Mln

Net Profit

$-646.00 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
InhibrxÂ Inc (INBX)	56.2	49.7	19.8	350.4	89.6	32.8	--
BSE Sensex^*	-9.1	-1.2	2.9	-3.6	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021
InhibrxÂ Inc (INBX)	413.0	-59.2	54.2	-43.6	32.5
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3
BSE Sensex	9.1	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
InhibrxÂ Inc (INBX)	123.4	1,816.3	0.0	-138.2	--	--	--	212.3
Arrowhead Pharmaceuticals (ARWR)	84.9	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	247.9	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	72.1	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	105.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	351.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	533.8	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	600.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About InhibrxÂ Inc (INBX)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent... therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. Read more

Founder, Chairman, President & CEO

Mr. Mark Paul Lappe
Founder, Chairman, President & CEO

Mr. Mark Paul Lappe
Headquarters

La Jolla, CA
Website

https://inhibrx.com

FAQs for InhibrxÂ Inc (INBX)

What is the current share price of InhibrxÂ Inc (INBX) Today?

The share price of InhibrxÂ Inc (INBX) is $123.41 (NASDAQ) as of 28-Aug-2026 16:00 EDT. InhibrxÂ Inc (INBX) has given a return of 89.62% in the last 3 years.

What is the current PB & PE ratio of InhibrxÂ Inc (INBX)?

Since, TTM earnings of InhibrxÂ Inc (INBX) is negative, P/E ratio is not available.
The P/B ratio of InhibrxÂ Inc (INBX) is 212.28 times as on 28-Aug-2026, a 3998 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.